CASE SERIES

Pituitary apoplexy presenting as isolated third cranial nerve palsy: case series

Ramesh Shrestha*, Suresh Bishokarma, Sushil Rayamajhi, Sunita Shrestha, Saurav Lamichhane, Pratyush Shrestha and Suraj Thulung

Department of Neurosurgery, Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu 44600, Nepal
*Correspondence address. Department of Neurosurgery, Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu 44600, Nepal. Tel: +977-9863856230; E-mail: the1ramesh.stha@gmail.com

Abstract

Pituitary apoplexy (PA) is caused by a sudden increase in pressure in the pituitary region due to acute hemorrhage, infarction or necrosis. PA can also be caused by a clinical restriction of symptoms such as sudden onset headache, visual disturbances and ophthalmoplegia due to third, fourth or sixth cranial nerve (CN) involvement [1]. PA has a prevalence of ~6.2 cases per 100,000 population and an annual incidence of 0.17 cases per 100,000 population [2, 3]. Isolated third CN palsy is a rare symptom of PA [5]. We presented the case reports of two patients who had acute isolated third CN palsy secondary to pathologically proven PA with variable healing processes.

INTRODUCTION

Pituitary apoplexy (PA) is a sudden neurological deficit caused by an expanding mass within the sella turcica, which may develop from pituitary hemorrhage, infarction or both, or from a pre-existing pituitary tumor such as an adenoma [1]. As a result, it is associated with a clinical constellation of symptoms such as sudden onset headache, visual disturbances and ophthalmoplegia due to third, fourth or sixth cranial nerve (CN) involvement [1]. PA has a prevalence of ~6.2 cases per 100,000 population and an annual incidence of 0.17 cases per 100,000 population [2, 3]. Isolated third CN palsy is a rare symptom of PA [5]. We presented the case reports of two patients who had acute isolated third CN palsy secondary to pathologically proven PA with variable healing processes.

CASE REPORT

Case 1

A 56-year-old hypertensive man presented to our emergency department with a chronic frontotemporal headache that had been worsening for 2 days and was associated with acute left ptosis without blurred vision or diplopia. There had been no loss of consciousness or seizures. On examination, his Glasgow coma scale (GCS) was 15/15. The right pupil was 3 mm light reactive, whereas the left was 4 mm non-responsive. Visual acuity and visual field circumference were normal in both eyes.

Magnetic resonance imaging (MRI) (axial T1, axial T2, coronal T1 and sagittal T1-weighted images) revealed a sellar and suprasellar lesion measuring 3 × 2.9 × 1.8 cm with patchy areas of high signal on T1-weighted images and signal void on T2-weighted images suggestive of hemorrhage. The suprasellar component of the lesion was displacing optic chiasma superiorly and the sellar component was causing sellar expansion with mass effect on bilateral cavernous sinuses (left > right); right internal carotid artery (ICA) had a contact angle of 90°, whereas left ICA had >90° (Fig. 1).

Preoperative hormone analysis showed normal levels of thyroid-stimulating hormone (TSH), growth hormone (GH), insulin-like growth factor (IGF), follicle-stimulating hormone (FSH), prolactin, free thyroxine, cortisol and luteinizing hormone (LH) levels.

PA was diagnosed when radiographic findings showed acute pituitary hemorrhage and subsequent pituitary adenectomy was planned, but surgery was delayed up to 13 days because of non-critical coronary artery disease detected on coronary angiography. When his condition stabilized, he underwent surgery. The tumor was soft to firm and a safe maximal resection was performed. Hemostasis was achieved and sella packed with fat harvested from the subcutaneous fat of the abdomen. Postoperatively, he suffered transient diabetes insipidus, which was treated with desmopressin injections and resolved by day 5 postoperatively. He was then discharged on the 8th postoperative day. At the time of discharge, he had residual ptosis, which gradually improved over 2 weeks based on clinical assessment at the outpatient visit. He fully recovered from ptosis over a month. Postoperative imaging performed at 6 weeks showed a residual tumor measuring 1.9 × 1.5 × 1.1 cm with no significant mass effect on the cavernous

Received: June 17, 2022. Accepted: August 7, 2022
Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2022.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Case 2

A 50-year-old gentleman presented with painful ptosis of the left eye for 4 days with no signs of raised intracranial pressure, seizure or loss of consciousness. Clinically, GCS was 15/15. The right pupil was 2 mm reactive to light, whereas the left pupil was 4 mm sluggishly reactive, with no signs of meningism.

MRI imaging showed a 2 × 1.6 × 1.6 cm sized sellar lesion arising from the pituitary fossa with an intrinsic high T1 signal in the periphery, extending superiorly in the suprasellar region and laterally, causing a mass effect on the left cavernous sinus. A signal void was seen in T2-weighted images suggestive of hemorrhage (Fig. 3).

A preoperative hormonal evaluation was performed, which showed normal levels of TSH, GH, IGF, FSH, prolactin, free thyroxine, cortisol and LH.

The patient underwent transsphenoidal pituitary adenectomy 3 days after admission. Intraoperatively, soft tumors with hemorrhagic components were seen. Hemostasis was achieved and the sella was packed with fat. The patient was managed in the ICU for 2 days and discharged on the 8th postoperative day. The ptosis gradually improved within 2 days of surgery, and during the 2-week follow-up in the outpatient clinic, the ptosis recovered completely. Follow-up imaging showed no evidence of a residual lesion in sella turcica (Fig. 4).

DISCUSSION

PA is a rare medical emergency caused by a growing mass within the sella turcica, secondary to pituitary hemorrhage or infarction, or within a pre-existing pituitary adenoma [1]. We reported on two
Pituitary apoplexy presenting as isolated third cranial nerve palsy

According to recent epidemiological studies, it has an annual incidence of 0.17 per 100,000 people and a prevalence of ~6.2 cases per 100,000 people [3, 4, 6]. In >80% of cases, PA is the first presentation of an underlying pituitary tumor and is characterized by rapid onset headache, which is usually the most common initial symptom, along with visual disturbances, ocular paralysis and acute onset hypopituitarism [2]. More than half of PA patients experience vision problems caused by a sudden increase in tumor mass, resulting in compression of the optic sacrum or optic nerves from an upward tumor extension [7]. The age- and sex-adjusted annual incidence of acquired third nerve palsy was 4.0 per 100,000 people [6].

A third CN palsy as a presentation of PA is rarely present [5]. It is characterized by a combination of ptosis, impaired pupillary constriction and ophthalmoparesis, depending on where the lesion is between the midbrain and orbit. Microvascular ischemia caused by diabetes or systemic hypertension, inflammatory processes such as giant cell arteritis, trauma, compressive mass lesions, i.e. intracranial tumors, or aneurysms are all major causes of third CN palsy [8].

The differential diagnosis of third CN palsy can be narrowed down by the presence or absence of accompanying pain and pupillomotor impairment. Compression lesions, particularly aneurysms, result in pupillary involvement, and isolated complete third nerve palsy with normal pupillary function characterizes ischemic lesions [8]. Compression lesions, such as posterior communicating artery aneurysms or tumors, usually involve both the superficial and deep fibers, resulting in oculomotor deficits and pupillary dysfunction. However, while ischemic lesions usually affect the central core of the nerve that controls oculomotor function, the superficial parasympathetic fibers are usually unaffected (pupil spares third nerve palsy) [9].

Several explanations have been proposed to explain why PA causes third nerve palsy. Because the oculomotor nerve lies horizontally in the same plane as the pituitary gland in the lateral wall of the cavernous sinus, it is often the first CN involved in the lateral spread of a pituitary tumor or hematoma [10]. Because CNs are sensitive to pressure, a sudden increase in pressure in the pituitary region due to acute hemorrhage, infarction or pituitary necrosis can be transmitted to the third CN with relative ease [11]. Acute third nerve palsy can also be caused by a reduction in the blood supply to the nerve due to compression of the vasa nervorum emanating from the ICA [12].

Imaging of our patient showed a sellar and suprasellar mass with an acute hemorrhagic component and a mild mass effect on the left cavernous sinus. As a result of this, in our patient, there is a high probability of pressure on the third CN or impairment of the vascular supply of the nerve due to compression of the vasa nervorum from the ICA as the cause of the third CN palsy. To prevent acute adrenal insufficiency, patients with PA require intravenous steroids until surgery. The definitive treatment for PA is neurosurgical decompression via a transsphenoidal approach. Early decompression can partially or fully restore pituitary and third CN function [13].

Patients who underwent surgery had better clinical improvement and endocrinological results since a viable tumor component could be removed from constrained areas such as the cavernous sinus [14]. However, in the recent study by Sipos et al. [15], conservative care is preferable to immediate neurosurgical intervention if the ophthalmoplegia is improving or stable. According to the literature, when visual acuity defects do not improve, surgery is performed in <7 days. Furthermore, this reduces the need for ongoing hormonal replacement [16].

Tumor size regression is directly related to better ophthalmologic and endocrinologic outcomes [17, 18]. Early intervention may be able to reverse or partially reverse pituitary function while preserving the third CN function [13]. The poor surgical outcomes could result from preoperative endocrine abnormalities [19]. A multidisciplinary approach, outcome reporting and institutional experience all have an impact on the outcome. Hence, before recommending evidence-based guidelines, a prospective study is required [20]. In order to determine the best immediate management with neurosurgical decompression via a transsphenoidal approach for PA, authors have suggested that patients with large tumors (>11.67 mm) or higher Knosp should be evaluated on a case-by-case basis [21].

Our patients underwent transsphenoidal neurosurgical decompression and pathological examination, confirming the diagnosis of PA. After the operation, the third CN palsy was completely resolved. The first patient underwent delayed decompression due to cardiac problems where recovery of third nerve function was delayed compared with the early decompression in the second patient. This finding may favor early decompression to restore the function of the third nerve palsy.

CONCLUSION

PA is an essential differential diagnosis in patients with isolated third nerve palsy. The prognosis for isolated third nerve palsy in PA appeared successful with variable recovery with medical and surgical interventions.

ACKNOWLEDGMENT

The authors would like to thank all attending physicians from the Department of Neurosurgery, Neurology and Radiology.

CONFLICT OF INTEREST STATEMENT

None declared.

FUNDING

None.

ETHICAL APPROVAL

Ethical approval was obtained from the IRC of Upendra Devkota Memorial National Institute of Neurological and Allied Sciences.

CONSENT

The patient gave written informed consent to publish the images and the article.

GUARANTOR

Dr Suresh Bishokarma and Dr Ramesh Shrestha.
REFERENCES

1. Verrees M, Arafah BM, Selman WR. Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg Focus 2004;16:E6.

2. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 1999;51:181–8.

3. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010;72:377–82.

4. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010;95:4268–75.

5. Rosso M, Ramaswamy S, Sucharew H, Vagal A, Anziska Y, Levine SR. Isolated third cranial nerve palsy in pituitary apoplexy: case report and systematic review. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 2021;30:105969.

6. Fang C, Leavitt JA, Hodge DO, Holmes JM, Mohney BG, Chen JJ. Incidence and etiologies of acquired third nerve palsy using a population-based method. JAMA Ophthalmol 2017;135:23–8.

7. Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P. Pituitary apoplexy. Endocr Rev 2015;36:622–45.

8. Bruce BB, Bioussé V, Newman NJ. Third nerve palsies. Semin Neurol 2007;27:257–68.

9. Asbury AK, Aldredge H, Hershberg R, Fisher CM. Oculomotor palsy in diabetes mellitus: a clinico-pathological study. Brain J Neurol 1970;93:555–66.

10. Rossitch E, Carrazana EJ, Black PM. Isolated oculomotor nerve palsy following apoplexy of a pituitary adenoma. J Neurosurg Sci 1992;36:103–5.

11. Zayour DH, Selman WR, Arafah BM. Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function. J Clin Endocrinol Metab 2004;89:5649–54.

12. Cahill M, Bannigan J, Eustace P. Anatomy of the extraneural blood supply to the intracranial oculomotor nerve. Br J Ophthalmol 1996;80:177–81.

13. Cho WJ, Joo SP, Kim TS, Seo BR. Pituitary apoplexy presenting as isolated third cranial nerve palsy with ptosis: two case reports. J Korean Neurosurg Soc 2009;45:118–21.

14. Messerer M, De Battista JC, Raverot G, Kassiss S, Dubourg J, Lapras V, et al. Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. Neurosurg Focus 2011;30:E11.

15. Sipos L, Szűcs N, Várallyay P. Pituitary apoplexy: surgical or conservative management? Orv Hetil 2021;162:1520–5.

16. Seo Y, Kim YH, Dho YS, Kim JH, Kim JW, Park CK, et al. The outcomes of pituitary apoplexy with conservative treatment: experiences at a single institution. World Neurosurg 2018;115:e703–10.

17. Almeida JP, Sanchez MM, Karekezi C, Warsi N, Fernández-Gajardo R, Panwar J, et al. Pituitary apoplexy: results of surgical and conservative management clinical series and review of the literature. World Neurosurg 2019;130:e988–99.

18. Teixeira JC, Lavrador J, Simão D, Miguéns J. Pituitary apoplexy: should endoscopic surgery be the gold standard? World Neurosurg 2018;111:e495–9.

19. Zhu Q, Liang Y, Fan Z, Liu Y, Zhou C, Zhang H, et al. Ischemic infarction of pituitary apoplexy: a retrospective study of 46 cases from a single tertiary center. Front Neurosci 2022;15:808111.

20. Abdulhaki A, Kanaan I. The impact of surgical timing on visual outcome in pituitary apoplexy: literature review and case illustration. Surg Neurol Int 2017;8:16.

21. Sousa D, Marques O, Almeida R. Pituitary apoplexy: surgical or conservative management. Endocr Abstr 2014;35:F926.